Literature DB >> 9176775

Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma.

M A Murphy1, C E Thirkill, W M Hart.   

Abstract

We present the case of a 74-year-old man with rapidly progressive bilateral visual loss, optic disc pallor, retinal arteriolar attenuation, and an abnormal electroretinogram with a 90% reduction in cone function and a 50% reduction in rod function. He was examined for a suspected cancer-associated retinopathy (CAR). Although he was found not to have expressed the previously reported 23-kd CAR antibody, high titers were found of an antibody to a 60-kd retinal protein, which as yet remains unidentified. An initial clinical search for an underlying cancer was unsuccessful, but 2 months later a mediastinal mass was found on chest x-rays, and biopsy confirmed a diagnosis of small-cell lung carcinoma. Combined therapy with oral corticosteroids and plasmapheresis resulted in a recovery of vision from counting fingers to 20/200 in the right eye and 20/40 to 20/25 in the left eye. Conventional chemotherapeutic management of the small-cell lung carcinoma was instituted, and the modest visual recovery was maintained. The visual improvement as well as lung tumor regression were accompanied by a decline in antibody titers from 1:2,000 pretreatment to 1:200 during the course of therapy. The absence of reactivity with the previously described 23-kd retinal antigen of the CAR syndrome does not exclude the diagnosis of paraneoplastic retinopathy in patients fitting the clinical profile of this disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176775

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  16 in total

Review 1.  Retinopathies associated with antiretinal antibodies.

Authors:  J J Hooks; M O Tso; B Detrick
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 2.  The need for standardization of antiretinal antibody detection and measurement.

Authors:  Farzin Forooghian; Ian M Macdonald; John R Heckenlively; Elise Héon; Lynn K Gordon; John J Hooks; Barbara Detrick; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2008-07-30       Impact factor: 5.258

3.  Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer.

Authors:  Grazyna Adamus
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-03-09       Impact factor: 4.799

4.  Small cell lung cancer and progressive retinopathy.

Authors:  Mami Morita; Tatsuro Fukuhara; Hidetoshi Takahashi; Makoto Maemondo
Journal:  BMJ Case Rep       Date:  2014-11-24

5.  Cancer-associated Retinopathy Developing After 10 Years of Complete Breast Cancer Remission.

Authors:  Nozomi Igarashi; Hiromasa Sawamura; Toshikatsu Kaburaki; Makoto Aihara
Journal:  Neuroophthalmology       Date:  2018-05-23

6.  Autoimmune retinopathy: clinical, electrophysiological, and immunological features in nine patients with long-term follow-up.

Authors:  Khaled Safadi; Itay Chowers; Eyal Banin; Boris Rosin; Liran Tiosano; Radgonde Amer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-30       Impact factor: 3.117

7.  Paraneoplastic Retinopathy/Optic Neuropathy.

Authors:  Denise M Damek
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

8.  Successful treatment of cancer-associated retinopathy with alemtuzumab.

Authors:  Ladan Espandar; Susan O'Brien; Charles Thirkill; Linda A Lubecki; Bita Esmaeli
Journal:  J Neurooncol       Date:  2007-01-25       Impact factor: 4.506

9.  Cancer-associated retinopathy in patients with breast carcinoma.

Authors:  Marta Misiuk-Hojło; Maria Ejma; Wojciech A Gorczyca; Stanisław Szymaniec; Danuta Witkowska; Wojciech Fortuna; Ryszard Miedzybrodzki; Jadwiga Rogozińska-Szczepka; Wiesława Bartnik
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-07-23       Impact factor: 4.291

Review 10.  Management of paraneoplastic syndromes in lung cancer.

Authors:  Leno Thomas; Young Kwok; Martin J Edelman
Journal:  Curr Treat Options Oncol       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.